| ¿µ¹® | Papanicolaou smear(test) | ÇÑ±Û | ÆÄÆÄ´ÏÄÝ·Î µµ¸»°Ë»ç |
|---|---|---|---|
| ¼³¸í | ÁÙ¿©¼ ÆËµµ¸»°Ë»ç(Pap smear)À̶ó°í ºÎ¸¥´Ù. ¿©¼ºÀÇ Àڱøñ¾ÏÀÇ ¹ß»ýÀ» ¹Ì¸® ¾Ë¾Æº¸±â À§ÇØ ½ÃÇàÇÏ´Â °Ë»ç¹ýÀ¸·Î ¹Ì±¹¿¡¼´Â ÀÌ ¹æ¹ýÀ¸·Î ÇöÀç Àڱøñ¾Ï¹ß»ý¿¡ ÀÇÇÑ »ç¸Á·üÀ» ÇöÀúÈ÷ ³·Ãß°í ÀÖ´Ù. ¹æ¹ýÀº »êºÎÀΰú¿¡¼ ½ÃÇàÇϸç, ¿©¼ºÀÇ Àڱøñ¿¡¼ ¼¼Æ÷¸¦ °¡Á®´Ù°¡ µµ¸»ÇÏ¿© Çö¹Ì°æÀ¸·Î °Ë»çÇÑ´Ù. ¿äÁîÀ½¿¡ ¿Í¼´Â Àڱøñ»Ó ¾Æ´Ï¶ó È£Èí±â³ª ºñ´¢±â µî ºÐºñ¹°À» µµ¸»ÇÏ¿© ÆÄÆÄ´ÏÄÝ·Î ¿°»öÀ» ÇÏ¿© °Ë»çÇÏ´Â °Íµµ ¿©±â¿¡ Æ÷ÇԵȴÙ. (±×¸² P-3). |
||
| ¿µ¹® | glucose tolerance test | ÇÑ±Û | Æ÷µµ´ç°ßµõ°Ë»ç |
|---|---|---|---|
| ¼³¸í | Æ÷µµ´ç°ßµõ °Ë»ç¶õ ´ç´¢º´ÀÇ Áø´Ü¿¡ »ç¿ëµÇ´Â °Ë»ç·Î ´çÀ» ü³»¿¡ Åõ¿©ÇÏ°í ½Ã°£ º°·Î Ç÷¾×À» äÃëÇÏ¿© Ç÷´çÀÇ ³óµµ¸¦ Àç¾î¼ °íÇ÷´ç ¿©ºÎ¸¦ Á¶»çÇÏ´Â °Ë»çÀÌ´Ù. ÁÖ·Î °æ±¸Æ÷µµ´ç°ßµõ°Ë»ç(oral glucose tolerance test)¸¦ ¸¹ÀÌ Çϴµ¥ À̰ÍÀº 10~16½Ã°£ÀÇ ±Ý½Ä ÈÄ¿¡ äÇ÷À» Çѹø Çѵڿ¡ µµ´ç 75gÀ» 250~300mLÀÇ ¹°¿¡ ³ì¿© 5ºÐ¿¡ °ÉÃļ ¸¶½Ã°Ô ÇÏ°í ¸Å½Ã°£ º°·Î äÇ÷À» ÇÏ¿© Ç÷´çÀÇ ³óµµ¸¦ ýũÇÑ´Ù. °øº¹½Ã¿¡ Á¤¸Æ¿¡¼ äÇ÷ÇÏ¿© ÃøÁ¤ÇÑ Ç÷´çÀÌ 140mg/dLÀÌ»óÀ̰ųª Æ÷µµ´ç°ßµõ °Ë»ç 2½Ã°£ÈÄÀÇ Ç÷´çÀÌ 200mg/dLÀÌ»óÀÏ °æ¿ì¿¡´Â ´ç´¢º´À¸·Î Áø´ÜÀ» ÇÑ´Ù. ±×·¯³ª ÀÌ °Ë»ç¸¦ ½Ç½ÃÇÒ °æ¿ì¿¡ ÁÖÀÇÇØ¾ß ÇÒ Á¡Àº °Ë»çÀü 3Àϰ£ ÇÏ·ç¿¡ 150gÀÌ»óÀÇ Åº¼öȹ°À» ¼·ÃëÇØ¾ß ÇÑ´Ù´Â °Í°ú °Ë»çµµÁß¿¡ ¿îµ¿, Èí¿¬ µîÀ» ÇÏÁö ¾Ê¾Æ¾ß ÇÑ´Ù´Â °ÍÀÌ´Ù. |
||
| ¿µ¹® | blood test | ÇÑ±Û | Ç÷¾×°Ë»ç |
|---|---|---|---|
| ¼³¸í | Ç÷¾×ÇüÀ̳ª Áúº´ À¯¹« µûÀ§¸¦ ¾Ë±â À§ÇÏ¿© ÇǸ¦ »Ì¾Æ ÇàÇÏ´Â °Ë»ç. ¸ö ÀüüÀÇ Àå±â³ª Á¶Á÷¿¡ º´ÅͰ¡ ÀÖÀ¸¸é ÀÌµé ¼ººÐ¿¡ º¯È°¡ ÀÖ°Ô µÇ¾î Áø´Ü¿¡ Å« µµ¿òÀ» ÁØ´Ù. |
||
| SRT | sedimentation rate test; simple reaction time; sinus node recovery time; sitting root test; speech r... |
|---|---|
| ST | esotropia; scala tympani; scaphotrapezoid; sclerotherapy; sedimentation time; semitendinosus; sensor... |
| AR | absolute risk; accounts receivable; achievement ratio; actinic reticuloid [syndrome]; active resista... |
| GA | Gamblers Anonymous; gastric analysis; gastric antrum; general anesthesia; general angiography; gener... |
| IA | ibotenic acid; immune adherence; immunoadsorbent; immunobiologic activity; impedance angle; indolami... |
| leukocyte cream | <haematology> Thin yellow white layer of leucocytes on top of the mass of red cells when whole blood is centrifuged. (18 Nov 1997) |
|---|---|
| leukocyte disorders | Disordered formation of various types of leukocytes or an abnormal accumulation or deficiency of these cells. (12 Dec 1998) |
| leukocyte elastase | <enzyme> An enzyme that catalyses the hydrolysis of proteins, including elastin. It cleaves preferentially bonds at the carboxyl side of ala and val, with greater specificity for ala. Registry number: EC 3.4.21.37 (12 Dec 1998) |
| leukocyte esterase | <enzyme> The presence of leukocyte esterase is indirect evidence for the presence of white blood cells in the urine. The standard urinalysis dip test allows for the quick determination of leukocyte esterase presence via a colour reaction on a urine test strip. A positive test indicates a urinary tract infection. (27 Sep 1997) |
| leukocyte inclusions | Discrete round or oval body's ranging in diameter from just visible to 2 um, which stain sky blue to gray blue with Romanowsky stains, found in neutrophils of patients with infections, burns, trauma, pregnancy, or cancer. Synonym: Dohle inclusions, leukocyte inclusions. (05 Mar 2000) |
| leukocyte interferon | <cytokine> One of the type I interferons produced by peripheral blood leukocytes or lymphoblastoid cells when exposed to live or inactivated virus, double-stranded RNA, or bacterial products. It is the major interferon produced by virus-induced leukocyte cultures and, in addition to its pronounced antiviral activity, causes activation of NK cells. It is used experimentally in the treatment of hairy-cell leukaemia. A number of different subtypes exist that are elaborated by leukocytes in response to viral infection or stimulation with double-stranded RNA; IFN-alpha-2A and -2B are protein products made by recombinant DNA techniques and are used as antineoplastic agents. See: interferon-alpha 2a, interferon-alpha 2b Synonym: leukocyte interferon. Pharmacological action: antineoplastic agent, antiviral agent. (20 Sep 2002) |
| leukocyte migration-inhibitory factors | Protein factor(s) released by sensitised lymphocytes (and possibly other cells) that inhibit the movement of leukocytes, especially polymorphonuclear cells, away from their site of release. Assays for these factors are used as tests for cellular immunity. Two of the common assays are the leukocyte migration capillary tube technique (lmct) and the leukocyte migration agarose technique (lmat). (12 Dec 1998) |
| leukocyte transfusion | The transfer of leukocytes from a donor to a recipient or reinfusion to the donor. (12 Dec 1998) |
| leukocyte tyrosine kinase receptor tyrosine kinase | <enzyme> May be receptor for pre-b lymphocyte growth or differentiation factor; aa sequence given in first source Registry number: EC 2.7.1.- Synonym: ltk receptor tyrosine kinase, ltk receptor tk, ltk protein, leukocyte tyrosine kinase (ltk) (26 Jun 1999) |
| acetyl reduction assay | <investigation> A technique for measuring the nitrogen fixation activity in photosynthetic organisms. It uses a flame ionisation detector and a gas chromatography apparatus to determine the reduction of acetylene to ethylene by the enzyme nitrogenase. (06 May 1997) |
| Ames assay | <procedure> One of a number of procedures used to test substances for likely ability to cause cancer that combines the use of animal tissue to generate active metabolites of the substance with a test for mutagenicity in bacteria. (18 Nov 1997) |
| antibiotic assay | <investigation> A test to determine how sensitive a bacterial or fungal strain is to arange of antibiotics bymeasuring the microbes' ability to grow in astandard dilution of each chemical. (09 Oct 1997) |
| assay | <procedure> The determination of the amount of a particular constituent of a mixture or of the biological or pharmacological potency of a drug. (10 May 1997) |
| bandshift assay | <investigation> An assay for proteins, such as transcription factors, that bind specific DNA sequences. A labelled oligonucleotide corresponding to the recognition sequence is incubated with an appropriate nuclear protein extract and run on a nondenaturing acrylamide gel. Oligonucleotides that have been bound by proteins are retarded relative to those that are unbound. (18 Nov 1997) |
| biological assay | <technique> Once a pharmaceutical protein is isolated from the cells in which it was grown, researchers perform tests to measure the protein's biological activity. It must maintain a certain minimal level of biological activity to be used for animal or clinical testing or, later, for market. Researchers also test to confirm that the isolated protein is identical to the desired protein. (21 Mar 1998) |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|